Top

Published in:

01-06-2012 | Progress in Hematology

Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy

Authors: Hiroshi Watarai, Daisuke Yamada, Shin-ichiro Fujii, Masaru Taniguchi, Haruhiko Koseki

Published in: International Journal of Hematology | Issue 6/2012

Abstract

Invariant natural killer T (iNKT) cells are characterized by the expression of an invariant Vα14–Jα18 paired with Vβ8/7/2 in mice, and Vα24–Jα18 with Vβ11 in humans, that recognizes glycolipids, such as α-galactosylceramide (α-GalCer), presented on the MHC class I-like molecule, CD1d. iNKT cells act as innate T lymphocytes and serve as a bridge between the innate and acquired immune systems. iNKT cells augment anti-tumor responses by producing IFN-γ, which acts on NK cells to eliminate MHC-non-restricted (MHC⁻) target tumor cells, and on CD8⁺ cytotoxic T lymphocytes to directly kill MHC-restricted (MHC⁺) tumor cells. Thus, when iNKT cells are activated by α-GalCer-pulsed dendritic cells, both MHC⁻ and MHC⁺ tumor cells can be effectively eliminated. Both of these tumor cell types are simultaneously present in cancer patients, and at present iNKT cells are only the cell type capable of eliminating them. Based on these findings, we have developed iNKT cell-targeted adjuvant immunotherapies with strong anti-tumor activity in humans. However, two-thirds of patients were ineligible for this therapy due to the limited numbers of iNKT cells in their bodies. In order to overcome the problem in cancer patients, we successfully established a method to generate iNKT cells with adjuvant activity from embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). In this review, we would like to outline the clinical potential for iNKT cells derived from ESCs and iPSCs for cancer immunotherapy, and the technical hurdles that must be overcome if we achieve effective ESC/iPSC-mediated cancer therapies.

Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483–513.PubMedCrossRef

Lantz O, Bendelac A. An invariant T cell receptor α chain is used by a unique subset of major histocompatibility complex class I-specific CD4⁺ and CD4⁻8⁻ T cells in mice and humans. J Exp Med. 1994;180:1097–106.PubMedCrossRef

Bendelac A. Positive selection of mouse NK1⁺ T cells by CD1-expressing cortical thymocytes. J Exp Med. 1995;182:2091–6.PubMedCrossRef

Bendelac A, Lantz O, Quimby ME, et al. CD1 recognition by mouse NK1⁺ T lymphocytes. Science. 1995;268:863–5.PubMedCrossRef

Exley M, Garcia J, Balk SP, et al. Requirements for CD1d recognition by human invariant Vα24⁺CD4⁻CD8⁻ T cells. J Exp Med. 1997;186:109–20.PubMedCrossRef

Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Valpha14 NKT cells by glycosylceramides. Science. 1997;278:1626–9.PubMedCrossRef

Cui J, Shin T, Kawano T, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623–6.PubMedCrossRef

Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297–336.PubMedCrossRef

Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003;4:1164–5.PubMedCrossRef

10.

Michel ML, Keller AC, Paget C, et al. Identification of an IL-17-producing NK1.1^neg iNKT cell population involved in airway neutrophilia. J Exp Med. 2007;204:995–1001.PubMedCrossRef

11.

Tomura M, Yu WG, Ahn HJ, et al. A novel function of Vα14⁺CD4⁺ NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol. 1999;163:93–101.PubMed

12.

Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121–8.PubMedCrossRef

13.

Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, et al. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA. 2000;97:8461–6.PubMedCrossRef

14.

Trobonjaca Z, Leithäuser F, Möller P, et al. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-γ release by liver NKT cells. J Immunol. 2001;167:1413–22.PubMed

15.

Stober D, Jomantaite I, Schirmbeck R, et al. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8⁺ T cells in vivo. J Immunol. 2003;170:2540–8.PubMed

16.

Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4⁺ and CD8⁺ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171:5140–7.PubMed

17.

Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198:267–79.PubMedCrossRef

18.

Fujii S, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607–18.PubMedCrossRef

19.

Fujii S, Shimizu K, Hemmi H, et al. Innate Vα14⁺ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007;220:183–98.PubMedCrossRef

20.

Khong HT, Restifo NP. Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol. 2002;3:999–1005.PubMedCrossRef

21.

Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13–27.PubMedCrossRef

22.

Toura I, Kawano T, Akutsu Y, et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with a-galactosylceramide. J Immunol. 1999;163:2387–91.PubMed

23.

Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Vα24⁺Vβ11⁺ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004;103:383–9.PubMedCrossRef

24.

Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503–17.PubMedCrossRef

25.

Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910–7.PubMedCrossRef

26.

Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006;12:6079–86.PubMedCrossRef

27.

Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 2008;99:638–45.PubMedCrossRef

28.

Motohashi S, Nagato K, Kunii N, et al. A phase I–II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009;182:2492–501.PubMedCrossRef

29.

Nakayama N, Fang I, Elliott G. Natural killer and B-lymphoid potential in CD34⁺ cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood. 1998;91:2283–95.PubMed

30.

Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265:1098–101.PubMedCrossRef

31.

Cho SK, Webber TD, Carlyle JR, et al. Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. Proc Natl Acad Sci USA. 1999;96:9797–802.PubMedCrossRef

32.

de Pooter RF, Cho SK, Carlyle JR, et al. In vitro generation of T lymphocytes from embryonic stem cell-derived prehematopoietic progenitors. Blood. 2003;102:1649–53.PubMedCrossRef

33.

Schmitt TM, de Pooter RF, Gronski MA, et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol. 2004;5:410–7.PubMedCrossRef

34.

Hochedlinger K, Jaenisch R. Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature. 2002;415:1035–8.PubMedCrossRef

35.

Inoue K, Wakao H, Ogonuki N, et al. Generation of cloned mice by direct nuclear transfer from natural killer T cells. Curr Biol. 2005;15:1114–8.PubMedCrossRef

36.

Watarai H, Rybouchkin A, Hongo N, et al. Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Vα14–Jα18 TCRα gene. Blood. 2010;115:230–7.PubMedCrossRef

37.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.PubMedCrossRef

38.

Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313–7.PubMedCrossRef

39.

Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007;448:318–24.PubMedCrossRef

40.

Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature. 2009;460:1132–5.PubMedCrossRef

41.

Schmitt TM, Zúñiga-Pflücker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17:749–56.PubMedCrossRef

42.

Benlagha K, Kyin T, Beavis A, et al. A thymic precursor to the NK T cell lineage. Science. 2002;296:553–5.PubMedCrossRef

43.

Pellicci DG, Hammond KJ, Uldrich AP, et al. A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(−)CD4(+) CD1d-dependent precursor stage. J. J Exp Med. 2002;195:835–44.PubMedCrossRef

44.

Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008;133:250–64.PubMedCrossRef

45.

Brown M, Rondon E, Rajesh D, et al. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One. 2010;5:e11373.

46.

Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11–4.PubMedCrossRef

47.

Loh YH, Hartung O, Li H, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7:15–9.PubMedCrossRef

48.

Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20–4.PubMedCrossRef

49.

Watarai H, Nakagawa R, Omori-Miyake M, et al. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc. 2008;3:70–8.PubMedCrossRef

50.

Watarai H, Fujii S, Yamada D, et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest. 2010;120:2610–8.PubMedCrossRef

51.

Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11–4.PubMedCrossRef

52.

Soldner F, Laganiere J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318–31.PubMedCrossRef

53.

Chen F, Pruett-Miller SM, Huang Y, et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods. 2011;8:753–5.PubMedCrossRef

Title: Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy
Authors: Hiroshi Watarai
Daisuke Yamada
Shin-ichiro Fujii
Masaru Taniguchi
Haruhiko Koseki
Publication date: 01-06-2012
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 6/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-012-1091-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Characterization of hemangioblast in umbilical arteries of mid-gestation mouse embryos

Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis

A case of hemoglobin Hiroshima (β146 histidine to aspartic acid) with compensatory erythremia and undetectable HbA1c

Detection of serum tumor markers in multiple myeloma using the CLINPROT system

T-cell prolymphocytic leukemia in Japan: is it a variant?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer